Cox hazard analysis of cause-specific survival in all cases
| Variable | Univariate analysis | P value | Multivariate analysis | P value |
| HR (95% CI) | HR (95% CI) | |||
| (A) Disease free survival | ||||
| Age | 1.015 (0.985 to 1.046) | 0.3295 | ||
| Size | 1.445 (1.265 to 1.650) | <0.0001 | 1.422 (1.221 to 1.657) | <0.0001 |
| Nuclear grade (1–2 vs 3) | 0.413 (0.195 to 0.874) | 0.0209 | 1.255 (0.506 to 3.112) | 0.6233 |
| TNBC or NTNBC | 3.129 (1.560 to 6.276) | 0.0013 | 2.490 (1.068 to 5.806) | 0.0346 |
| LAT1 score (0–4 vs 6–9) | 3.798 (1.706 to 8.457) | 0.0011 | 0.989 (0.844 to 1.159) | 0.887 |
| CD98hc score (0–4 vs 6–9) | 2.538 (1.201 to 5.362) | 0.0146 | 1.153 (0.435 to 3.056) | 0.7743 |
| Ki-67 LI (≤20% vs >20%) | 3.641 (1.572 to 8.432) | 0.0026 | 2.274 (1.014 to 5.097) | 0.046 |
| lymph node metastasis | 3.170 (1.565 to 6.420) | 0.0014 | 2.708 (1.177 to 6.233) | 0.0192 |
| pStage (I vs II-III) | 3.640 (1.276 to 10.380) | 0.0157 | 0.810 (0.231 to 2.845) | 0.7424 |
| (B) Overall survival | ||||
| Age | 1.00 (0.959 to 1.043) | 0.997 | ||
| Size | 1.561 (1.302 to 1.870) | <0.0001 | 1.485 (1.206 to 1.830) | 0.0002 |
| Nuclear grade 1–2 vs 3 | 0.225 (0.64 to 0.790) | 0.0199 | 0.825 (0.102 to 3.535) | 0.7951 |
| TNBC or NTNBC | 4.655 (1.690 to 12.826) | 0.0029 | 3.150 (0.988 to 10.037) | 0.0523 |
| LAT1score 0–4 vs 6–9 | 8.502 (1.932 to 37.420) | 0.0046 | 2.339 (0.352 to 15.555) | 0.3792 |
| CD98hc score 0–4 vs 6–9 | 4.804 (1.368 to 16.869) | 0.0143 | 1.167 (0.238 to 5.728) | 0.8489 |
| Ki-67 LI (≤20% vs >20%) | 4.151 (1.182 to 14.575) | 0.0263 | 1.952 (0.442 to 8.626) | 0.3778 |
| lymph node metastasis | 4.594 (1.596 to 13.227) | 0.0047 | 3.015 (0.881 to 10.318) | 0.0788 |
| pStage (I vs II-III) | 7.845 (1.036 to 59.408) | 0.0461 | 1.202 (0.119 to 12.142) | 0.876 |
HR, Hazard ratio; LAT1, L-type amino acid transporter 1; LI, labelling index; NTNBC, non-triple-negative breast cancer; TNBC, triple-negative breast cancer.